Clinical Trial Update: Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) [Phase 3]

View source ↗

Summary

This document describes a Phase 3 long-term extension trial (EXTEND) to evaluate the safety and efficacy of CYB003 in major depressive disorder. Enrollment is b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• CYB003 (deuterated psilocin analog)

Snippet

Sponsor: Cybin IRL Limited | Conditions: Major Depressive Disorder | Phase 3 | Status: ENROLLING_BY_INVITATION